Neoleukin Therapeutics, Inc.
NLTX · NASDAQ
12/31/2024 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | $0 | $0 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | -98.7% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -1,011,633.3% | -10,546.3% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -1,011,533.3% | -7,378.5% |
| EPS Diluted | -3.96 | -5.07 | -5.5 | -3.2 |
| % Growth | 21.9% | 7.8% | -71.9% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |